Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een onderzoek naar Orelabrutinib bij patiënten met secundair progressieve multiple sclerose

30 oktober 2026 bijgewerkt door: Zenas BioPharma (USA), LLC

Een fase 3, gerandomiseerde, dubbelblinde, effectiviteits- en veiligheidsstudie waarbij Orelabrutinib wordt vergeleken met een placebo bij patiënten met niet-actieve secundair progressieve multiple sclerose

Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with non-active Secondary Progress MS. Patients will be treated for approximately 24 to 60 months, with a minimum treatment duration of 12 months. The study will enroll approximately 990 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.

Studie Overzicht

Gedetailleerde beschrijving

This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with naSPMS. The study will enroll approximately 990 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.

The study consists of the following periods:

  • Screening Period: Up to 4 weeks.
  • Treatment Period: The duration of treatment will vary for individual participants ranging from approximately 24 to 60 months, depending on the time of recruitment. A month is defined as a period of 28 days by convention.
  • Double-blinded (DB) Treatment: All eligible participants will be randomized at 2:1 ratio to accept orelabrutinib QD or placebo during the DB treatment period. The study will be unblinded when all participants in the DB period have reached a minimum treatment duration of 12 months at the time of primary analysis timing cutoff.
  • Open-label (OL) Treatment: Participants with 24-week CDP as assessed by EDSS are eligible for 2-year open-label orelabrutinib treatment.
  • Safety Follow-Up Period: It will last 4 weeks. The safety follow-up period will begin when the participants discontinue from the treatment before the end of the trial for any reasons or complete the trial but do not enter the long-term safety study (LTS) (see below).

All active study participants will have a final end of study (EOS) visit within 4 weeks of the study end date. Participants who are receiving IMP in DB or OL but do not consent to or are not eligible for enrollment in the LTS study, must return for a final safety follow-up visit 4 weeks later. For participants who intend and are eligible to join the LTS, open-label treatment with orelabrutinib will continue and no safety follow-up will occur.

Studietype

Ingrijpend

Inschrijving (Geschat)

990

Fase

  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

    • New South Wales
      • Kogarah, New South Wales, Australië, 2217
        • Werving
        • Southern Neurology Suite 2
    • Limburg
      • Overpelt, Limburg, België, 3900
        • Werving
        • MS-Netwerk Limburg - Revalidatie
      • Pleven, Bulgarije, 5800
        • Werving
        • Avis Medica Hospital Pleven
    • Plovdiv
      • Plovdiv, Plovdiv, Bulgarije, 4000
        • Werving
        • Medical Center Nevrocentrum
    • Sofia
      • Sofia, Sofia, Bulgarije, 1680
        • Werving
        • Diagnostic and Consultative Center Convex
      • Sofia, Sofia, Bulgarije, 1510
        • Werving
        • Medical Center Hera EOOD
    • Tarnovo
      • Veliko Tarnovo, Tarnovo, Bulgarije, 5000
        • Werving
        • Medical Center Medica Plus OOD
    • Hesse
      • Bad Homburg, Hesse, Duitsland, 61348
        • Werving
        • Zentrum fur klinische Forschung Dr.Scholl GmbH
    • Harju
      • Tallinn, Harju, Estland, 10617
        • Werving
        • Astra clinic (Clinic4U)
    • Gard
      • Nîmes, Gard, Frankrijk, 30029
        • Werving
        • Centre Hospitalier Universitaire de Nimes (CHU) - Hopital Universitaire Caremeau
      • Tbilisi, Georgië, 0114
        • Werving
        • LTD Pineo Medical Ecosystem
      • Tbilisi, Georgië, 0186
        • Werving
        • Raymann, LLC
      • Tbilisi, Georgië, 0159
        • Werving
        • NNLE Jo Ann University Hospital
      • Tbilisi, Georgië, 0186
        • Werving
        • Caucasus Medical Center Ltd
    • K'alak'i T'bilisi
      • Tbilisi, K'alak'i T'bilisi, Georgië, 0114
        • Werving
        • JSC Curatio
    • Saburtalo
      • Tbilisi, Saburtalo, Georgië, 0160
        • Werving
        • MD Georgia Staff Physician MediClub Georgia
    • Athens
      • Cholargós, Athens, Griekenland, 15562
        • Werving
        • Metropolitan General Hospital
    • Attica
      • Athens, Attica, Griekenland, 11526
        • Werving
        • Errikos Dunant Hospital
      • Budapest, Hongarije, 1145
        • Werving
        • National Institute of Clinical Neurosciences
      • Tatabánya, Hongarije, 2800
        • Werving
        • Komarom-Esztergom Varmegyei Szent Borbala Korhaz
    • Komarom-Esztergom Vamegye
      • Esztergom, Komarom-Esztergom Vamegye, Hongarije, 2500
        • Werving
        • Valeomed Kft.
    • Chieti
      • Chieti, Chieti, Italië, 66100
        • Werving
        • University G. D'Annunzio of Chieti-Pescara
    • Isernia/Molise
      • Pozzilli, Isernia/Molise, Italië, 86077
        • Werving
        • IRCCS Istituto Neurologico Mediterraneo Neuromed
      • Zagreb, Kroatië, 10 000
        • Werving
        • Klinicki Bolnicki Centar Zagreb-Rebro
    • Kauno
      • Kaunas, Kauno, Litouwen, 50161
        • Werving
        • Hospital of Lithuanian University of Health Sciences
      • Vinnytsia, Oekraïne, 21009
        • Werving
        • Medical Clinical Investigational Center of Medical Center LLC Health Clinic
    • Chernivtsi Oblast
      • Chernivtsi, Chernivtsi Oblast, Oekraïne, 58023
        • Werving
        • Regional Municipal Non-commercial Enterprise Chernivtsi Emergency Medical Hospital
    • Ivano-Frankivs'k Oblast
      • Ivano-Frankivsk, Ivano-Frankivs'k Oblast, Oekraïne, 76018
        • Werving
        • CNE City Clinical Hospital #1 of Ivano-Frankivsk council
    • Lviv Oblast
      • Lviv, Lviv Oblast, Oekraïne, 79000
        • Werving
        • Limited Liability Company Medical Center Neuroclinic
      • Lviv, Lviv Oblast, Oekraïne, 79029
        • Werving
        • Limited Liability Company "Neurofocus"
      • Lublin, Polen, 20-064
        • Werving
        • Galen Clinic
      • Poznan, Polen, 15-540
        • Werving
        • Prywatna Lecznica Certus Sp. z o.o.
      • Szczecin, Polen, 70-111
        • Werving
        • EUROMEDIS Osrodek Badan Klinicznych
      • Żory, Polen, 44-240
        • Werving
        • Centrum Medyczne ProNeuro Żory
    • Kuyavian-Pomeranian Voivodeship
      • Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Polen, 85-605
        • Werving
        • Centrum Medyczne INTERCOR Sp. z o.o.
    • Lublin Voivodeship
      • Lublin, Lublin Voivodeship, Polen, 20-601
        • Werving
        • Malva Trials
      • Lublin, Lublin Voivodeship, Polen, 20-064
        • Werving
        • Instytut Naukowo-Badawczy w Lublinie Sp. z o.o.
      • Lublin, Lublin Voivodeship, Polen, 20-064
        • Werving
        • NZOZ Neuromed M. i M. Nastaj Sp.P
    • Lubusz Voivodeship
      • Nowa Sól, Lubusz Voivodeship, Polen, 67-100
        • Werving
        • Twoja Przychodnia Centrum Medyczne Nowa Sól
    • Mazovian
      • Warsaw, Mazovian, Polen, 02-172
        • Werving
        • MTZ Clinical Researcz Powered by pratia
    • Rzeszów
      • Rzeszów, Rzeszów, Polen, 35-323
        • Werving
        • Nmedis sp. z o.o.
    • Silesian Voivodeship
      • Katowice, Silesian Voivodeship, Polen, 40-081
        • Werving
        • Centrum Medyczne Pratia Katowice
      • Katowice, Silesian Voivodeship, Polen, 40-571
        • Werving
        • MA-LEK Clinical Sp. z o.o.
      • Katowice, Silesian Voivodeship, Polen, 40-584
        • Werving
        • NZOZ Novo Med
    • Upper Silesia
      • Katowice, Upper Silesia, Polen, 40-686
        • Werving
        • Neuro Medic Clinic
    • Wielkopolska
      • Poznan, Wielkopolska, Polen, 61-853
        • Werving
        • Nzoz Neuro-Kard Ilkowski I Partnerzy Spolka Partnerska Lekarzy
      • Poznan, Wielkopolska, Polen, 60-324
        • Werving
        • Twoja Przychodnia PCM
    • Łódź Voivodeship
      • Lodz, Łódź Voivodeship, Polen, 91-743
        • Werving
        • PRO SALUS Sp. z o.o. sp.k.
      • Lodz, Łódź Voivodeship, Polen, 90-324
        • Werving
        • Centrum Neurologii Krzysztof Selmaj
      • Guaynabo, Puerto Rico, 00969
        • Werving
        • Caribbean Center for Clinical Research
    • Constanța County
      • Constanța, Constanța County, Roemenië, 900123
        • Werving
        • Spital Clinic CF Constanta
    • Suceava
      • Radauti, Suceava, Roemenië, 725400
        • Werving
        • Spitalul Municipal Sf. Doctori Cosma si Damian Radauti
      • Kragujevac, Servië, 34000
        • Werving
        • University Clinical Centre of Kragujevac
      • Niš, Servië, 18000
        • Werving
        • Clinic of Neurology - Clinical Center Nis
    • Belgrade
      • Belgrade, Belgrade, Servië, 11000
        • Werving
        • University Clinical Centre of Serbia
    • A Coruña
      • A Coruña, A Coruña, Spanje, 15006
        • Werving
        • Complejo Hospitalario Universitario A Coruña
    • Galicia
      • Vigo, Galicia, Spanje, 36312
        • Werving
        • Hospital Alvaro Cunqueiro
    • Madrid
      • Madrid, Madrid, Spanje, 28007
        • Werving
        • Hospital Gregorio Marañon
      • Majadahonda, Madrid, Spanje, 28222
        • Werving
        • Hospital Universitario Puerta de Hierro de Majadahonda
    • Málaga
      • Málaga, Málaga, Spanje, 29016
        • Werving
        • Vithas Hospital Parque San Antonio
    • Seville
      • Castilleja de la Cuesta, Seville, Spanje, 41950
        • Werving
        • Hospital Vithas Nisa Sevilla
      • Choceň, Tsjechië, 56501
        • Werving
        • NEUROHK, s.r.o.
      • Jihlava, Tsjechië, 58601
        • Werving
        • Regional Hospital Jihlava
    • Arizona
      • Phoenix, Arizona, Verenigde Staten, 85032
        • Werving
        • Arizona Neuroscience Research, LLC
      • Scottsdale, Arizona, Verenigde Staten, 85253
        • Werving
        • Perseverance Research Center, LLC (PRC)
    • California
      • Fullerton, California, Verenigde Staten, 92835
        • Werving
        • Fullerton Neurology and Headache Center
      • Torrance, California, Verenigde Staten, 90502-2006
        • Werving
        • Harbor-UCLA Medical Center - The Lundquist Institute (Los Angeles Biomedical Research Institute (LA BioMed))
      • West Hollywood, California, Verenigde Staten, 90048
        • Werving
        • Regina Berkovich MD, PhD Inc
    • Florida
      • Boca Raton, Florida, Verenigde Staten, 33487
        • Werving
        • SFM Clinical Research, LLC
      • Bradenton, Florida, Verenigde Staten, 34209
        • Werving
        • Nova Clinical Research, LLC
      • Clearwater, Florida, Verenigde Staten, 33761
        • Werving
        • MS and Neuromuscular Center of Excellence
      • Maitland, Florida, Verenigde Staten, 32751
        • Werving
        • Neurology Associates
      • Naples, Florida, Verenigde Staten, 34105
        • Werving
        • Aqualane Clinical Research
      • Tampa, Florida, Verenigde Staten, 33612
        • Werving
        • University of South Florida Department of Neurology - MS Division
    • Indiana
      • Indianapolis, Indiana, Verenigde Staten, 46256
        • Werving
        • Josephson Wallack Munshower Neurology, Pc Suite 225
    • Kansas
      • Kansas City, Kansas, Verenigde Staten, 66160
        • Werving
        • University of Kansas Medical Center
      • Roeland Park, Kansas, Verenigde Staten, 66205
        • Werving
        • KC Research Center, PA Neurology Research Dept
    • Massachusetts
      • Boston, Massachusetts, Verenigde Staten, 02131
        • Ingetrokken
        • Boston Clinical Trials
      • Worcester, Massachusetts, Verenigde Staten, 01655
        • Werving
        • University of Massachusetts Memorial Medical Center
    • Michigan
      • Rochester Hills, Michigan, Verenigde Staten, 48307
        • Werving
        • Profound Research LLC at Oakland Neurology Center
    • Missouri
      • St Louis, Missouri, Verenigde Staten, 63110
        • Werving
        • Washington University School of Medicine
    • New Mexico
      • Albuquerque, New Mexico, Verenigde Staten, 87131
        • Werving
        • University Of New Mexico School Of Medicine
    • New York
      • New York, New York, Verenigde Staten, 10029
        • Werving
        • Mount Sinai Medical Center
    • Ohio
      • Columbus, Ohio, Verenigde Staten, 43235
        • Werving
        • The Boster Center for Multiple Sclerosis
      • Columbus, Ohio, Verenigde Staten, 43221
        • Werving
        • The Ohio State University Wexner Medical Center (OSUWMC)
    • Oklahoma
      • Oklahoma City, Oklahoma, Verenigde Staten, 73104
        • Werving
        • OMRF Multiple Sclerosis Center of Excellence
    • South Carolina
      • Greenville, South Carolina, Verenigde Staten, 29605
        • Werving
        • Premier Neurology
    • Tennessee
      • Cordova, Tennessee, Verenigde Staten, 38018
        • Werving
        • Neurology Clinic, P.C.
    • Texas
      • San Antonio, Texas, Verenigde Staten, 78258
        • Werving
        • Lone Star Neurology
      • Sherman, Texas, Verenigde Staten, 75092
        • Werving
        • Texas Institute for Neurological Disorders - Sherman

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 60 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. 18 to 60 years of age, inclusive, at the time of signing the informed consent.
  2. Participant must have a previous diagnosis of RRMS in accordance with 2024 McDonald criteria
  3. Participant must have a current diagnosis of SPMS in accordance with the clinical course criteria revised in 2013
  4. Participant must have documented evidence of disability progression independent of clinical relapse observed during the 24 months before screening. A written summary of the clinical evidence of disability progression must be discussed and aligned between the Investigator and the Sponsor's dedicated qualified person(s).
  5. Absence of clinical relapses for at least 24 months.

Exclusion Criteria:

  1. The patient has been diagnosed with primary progressive MS (PPMS) according to 2024 McDonald diagnostic criteria
  2. Immunologic disorder other than MS or any other conditions requiring corticosteroid therapy.
  3. History or current diagnosis of other neurological disorders that may mimic MS
  4. History or current diagnosis of progressive multifocal leukoencephalopathy
  5. Active, clinically significant viral, bacterial, or fungal infection
  6. History of any other significant active medical condition
  7. History of suicidal behavior within 6 months prior to Screening
  8. Any prior history of malignancy
  9. Patients on anticoagulation, or antiplatelet therapy
  10. Patients took strong/moderate CYP3A inhibitors or strong/moderate CYP3A inducers within 14 days
  11. Clinically significant laboratory abnormalities at Screening.
  12. Vaccination with live or live-attenuated virus vaccine within 1 month prior to Screening
  13. History of alcohol abuse or alcohol use disorder or other drug abuse within 12 months prior to screening.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verviervoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Orelabrutinib Group

Orelabrutinib PO daily

Orelabrutinib orally

Placebo-vergelijker: Placebo Group

Placebo PO daily

Placebo orally

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Time to onset of confirmed disability progression (CDP) events, confirmed over at least 24 weeks
Tijdsspanne: Up to approximately 120 weeks

Expanded disability status scale (EDSS) score increase ≥ 1.0 point from baseline when the baseline score is ≤ 5.0, or ≥ 0.5 points from baseline when the baseline score is > 5.0

Up to approximately 120 weeks

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
12 Week CDP
Tijdsspanne: Up to approximately 120 weeks

Time to onset of CDP events on EDSS, confirmed over at least 12 weeks

Up to approximately 120 weeks
T2 lesions on MRI
Tijdsspanne: Up to approximately 120 weeks

The total number of new or enlarging T2 lesions on MRI scans of the brain

Up to approximately 120 weeks
24-week CDP-9-hole Peg Test
Tijdsspanne: Up to approximately 120 weeks

Time to onset of CDP events on 9-hole Peg Test (9HPT), defined as ≥ 20% increase on 9HPT from baseline, confirmed over at least 24 weeks

Up to approximately 120 weeks
24-week CDP-T25FWT
Tijdsspanne: Up to approximately 120 weeks

Time to onset of CDP events on Timed 25-Foot Walk Test (T25FWT), defined as ≥ 20% increase on T25FWT from baseline, confirmed over at least 24 weeks

Up to approximately 120 weeks
24-week CDI
Tijdsspanne: Up to approximately 120 weeks

Time to onset of confirmed disability improvement (CDI) events on EDSS, defined as ≥ 1.0-point decrease on the EDSS score from baseline when the baseline score is ≤ 5.0, or ≥ 0.5 points from baseline when the baseline score is > 5.0, confirmed over at least 24 weeks

Up to approximately 120 weeks
24-week CDI-9HPT
Tijdsspanne: Up to approximately 120 weeks

Time to onset of CDI events on 9HPT, defined as ≥ 20% decrease on the 9HPT score from baseline, confirmed over at least 24 weeks

Up to approximately 120 weeks
24-week CDI-T25FWT
Tijdsspanne: Up to approximately 120 weeks

Time to onset of CDI events on T25FWT, defined as ≥ 20% decrease on the T25FWT score from baseline, confirmed over at least 24 weeks

Up to approximately 120 weeks
Symbol Digit Modalities Test
Tijdsspanne: Up to approximately 120 weeks

The change in cognitive function as assessed by Symbol Digit Modalities Test (SDMT) from baseline to each scheduled visit

Up to approximately 120 weeks
Annualized relapse rate
Tijdsspanne: Up to approximately 120 weeks

Annualized relapse rate (ARR) during the study period assessed by protocol-defined adjudicated relapses

Up to approximately 120 weeks
To evaluate the safety and tolerability of orelabrutinib
Tijdsspanne: Up to approximately 120 weeks

Safety as assessed by the nature, severity, and incidence of adverse events (AEs) (graded according to National Cancer Institute-Common Terminology Criteria for AEs, NCI-CTCAE version 5.0);

Up to approximately 120 weeks

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

23 maart 2026

Primaire voltooiing (Geschat)

1 juni 2030

Studie voltooiing (Geschat)

1 juli 2030

Studieregistratiedata

Eerst ingediend

18 december 2025

Eerst ingediend dat voldeed aan de QC-criteria

19 december 2025

Eerst geplaatst (Werkelijk)

23 december 2025

Updates van studierecords

Laatste update geplaatst (Werkelijk)

4 november 2026

Laatste update ingediend die voldeed aan QC-criteria

30 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren